Implantation

Transcatheter Aortic Valve Replacement Market Size, Share & Trends Analysis Report By Implantation Procedure, By Material, By Mechanism, By End-Use, By Region And Segment Forecasts, 2023 - 2030

Retrieved on: 
Tuesday, March 14, 2023
Aortic stenosis, AR, Ageing, Cardiovascular disease, Patient, Stenosis, Heart, Prevalence, TAVR, American College, AS, Risk, Hospital, Growth, Nickel titanium, Woman, Cardiology, Implantation, USD, Rheumatic fever, Medical device, Pharmaceutical industry

NEW YORK, March 14, 2023 /PRNewswire/ -- Transcatheter Aortic Valve Replacement Market Size, Share & Trends Analysis Report By Implantation Procedure (Transfemoral, Transapical, Transaortic), By Material, By Mechanism, By End-Use, By Region, And Segment Forecasts, 2023 - 2030

Key Points: 
  • NEW YORK, March 14, 2023 /PRNewswire/ -- Transcatheter Aortic Valve Replacement Market Size, Share & Trends Analysis Report By Implantation Procedure (Transfemoral, Transapical, Transaortic), By Material, By Mechanism, By End-Use, By Region, And Segment Forecasts, 2023 - 2030
    The global transcatheter aortic valve replacement market size is expected to reach USD 10.2 billion by 2030, expanding at 7.2% CAGR from 2023 to 2030.
  • The rising geriatric population and the prevalence of risk factors like aortic valve stenosis (AS) and other diseases continue to drive the demand for transcatheter aortic valve replacement (TAVR) procedures.
  • According to the World Heart Federation 2022, rheumatic heart disease affected 39 million individuals globally.
  • Based on the implantation procedure, the transfemoral segment held the largest market share of 53.6% in terms of revenue in 2022.

Axcelis Announces Financial Results For Second Quarter 2021

Retrieved on: 
Wednesday, August 4, 2021
Axcelis Technologies, ACLS, Implantation, Ion implantation, Nasdaq, Finance, Companies, Physical sciences

BEVERLY, Mass., Aug. 4, 2021 /PRNewswire/ -- Axcelis Technologies , Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, today announced financial results for the second quarter ended June 30, 2021.

Key Points: 
  • BEVERLY, Mass., Aug. 4, 2021 /PRNewswire/ -- Axcelis Technologies , Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, today announced financial results for the second quarter ended June 30, 2021.
  • Highlights for the second quarter are as follows:
    The Company reported second quarter revenue of $147.3 million, compared to $132.8 million for the first quarter of 2021.
  • For the third quarter ending September 30, 2021, Axcelis expects revenues to be approximately $170 million.
  • The Company will host a call to discuss the results for the second quarter on Thursday, August 5, 2021 at 8:30 am ET.

Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

Retrieved on: 
Wednesday, June 23, 2021
Implantation, Implant, Itch

Following implantation of one TP-2021 prototype implant, the treated and untreated control mice were repeatedly challenged with 5'-GNTI.

Key Points: 
  • Following implantation of one TP-2021 prototype implant, the treated and untreated control mice were repeatedly challenged with 5'-GNTI.
  • The results from these studies demonstrated that the experimental TP-2021 implants provided sustained itch suppression for a period of 14 days post-implantation.
  • In addition, mice were sampled for pharmacokinetic analysis following subcutaneous acute injection with TP-2021 (0.3 mg/Kg) in saline or following implantation with one TP-2021 implant.
  • Chronic pruritus is an unpleasant and often debilitating condition, resulting in the need to scratch that lasts more than 6weeks.

Axcelis To Participate In The 13th Annual Virtual CEO Investor Summit 2021

Retrieved on: 
Tuesday, June 1, 2021
Axcelis Technologies, ACLS, Implantation, Summit, New Jersey

BEVERLY, Mass., June 1, 2021 /PRNewswire/ --Axcelis Technologies, Inc. (NASDAQ: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced that company management is scheduled to participate in the 13th Annual CEO Summit, being held virtually this year on June 15, 2021.

Key Points: 
  • BEVERLY, Mass., June 1, 2021 /PRNewswire/ --Axcelis Technologies, Inc. (NASDAQ: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced that company management is scheduled to participate in the 13th Annual CEO Summit, being held virtually this year on June 15, 2021.
  • The CEO Summit is hosted by executive management from participating companies and will feature a virtual "round-robin" format consisting of small group meetings, each 40 minutes in duration.
  • The Virtual CEO Summit is by invitation only and is open to accredited investors and publishing research analysts.
  • To RSVP for the Virtual CEO Summit, please contact either of the Summit's co-chairs.

Axcelis to Participate in the B. Riley Securities' Vision Day

Retrieved on: 
Wednesday, January 20, 2021
Axcelis Technologies, ACLS, Ion implantation, Implantation, Physical sciences, Electronics industry, Chemistry

Axcelis is scheduled to host a fireside chat on Thursday, January 28th at 3:30 p.m. Eastern Standard Time.

Key Points: 
  • Axcelis is scheduled to host a fireside chat on Thursday, January 28th at 3:30 p.m. Eastern Standard Time.
  • A replay of the webcast will be available after the event.
  • Axcelis (Nasdaq: ACLS), headquartered in Beverly, Mass., has been providing innovative, high-productivity solutions for the semiconductor industry for over 40 years.
  • Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation systems, one of the most critical and enabling steps in the IC manufacturing process.

Axcelis Updates And Increases Q4 2020 Guidance

Retrieved on: 
Tuesday, January 12, 2021
Axcelis Technologies, Finance, ACLS, Money, Earnings guidance, NASDAQ, Beverly, Massachusetts, Implantation, Financial economics

BEVERLY, Mass., Jan. 12, 2021 /PRNewswire/ --Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, today provided updated financial guidance for the fourth quarter of 2020.

Key Points: 
  • BEVERLY, Mass., Jan. 12, 2021 /PRNewswire/ --Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, today provided updated financial guidance for the fourth quarter of 2020.
  • The Company expects revenue for the fourth quarter of 2020 to be approximately $120 million, above the $110 million prior guidance.
  • As a result, the Company expects earnings per diluted share of approximately $0.32, up from the previous guidance of approximately $0.21.
  • Axcelis Technologies will release financial results for the fourth quarter and full year 2020 onWednesday, February 10, 2021at4:00 p.m. Eastern Time(ET).

Axcelis To Participate In The Benchmark Technology Conference

Retrieved on: 
Tuesday, November 3, 2020
Axcelis Technologies, ACLS, Ion implantation, Implantation, Physical sciences, Chemistry, Electronics industry

BEVERLY, Mass., Nov. 3, 2020 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate inthe Benchmark TechnologyConference.

Key Points: 
  • BEVERLY, Mass., Nov. 3, 2020 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate inthe Benchmark TechnologyConference.
  • Doug Lawson, executive vice president of corporate marketing and strategy, will host one-on-one meetings with interested investors during the conference.
  • For more information on the conference, or to schedule a one-on-one meeting, please contact Benchmark or visit the event website at https://www.benchmarkcompany.com/news-events/upcoming-events/technology-... .
  • Axcelis (Nasdaq: ACLS), headquartered in Beverly, Mass., has been providing innovative, high-productivity solutions for the semiconductor industry for over 40 years.

CorNeat Vision's Synthetic Cornea Approved for First-in-Human Implantation

Retrieved on: 
Tuesday, July 14, 2020
Medicine, Medical specialties, Clinical medicine, Ophthalmology, Eye surgery, Keratoprosthesis, Cornea, Implantation, Implant, Boston keratoprosthesis

The CorNeat KPro first-in-human implantation will be led by Professor Irit Bahar, Director of the Ophthalmology Department at Beilinson Hospital.

Key Points: 
  • The CorNeat KPro first-in-human implantation will be led by Professor Irit Bahar, Director of the Ophthalmology Department at Beilinson Hospital.
  • The CorNeat KPro implant is designed to replace deformed, scarred or opacified corneas and is expected to fully rehabilitate the vision of corneally blind patients immediately following implantation.
  • "We are extremely excited for the CorNeat KPro first-in-human implantation," said Gilad Litvin, M.D., CorNeat Vision's Chief Medical Officer and the KPro's inventor.
  • About the CorNeat KPro: The CorNeat KProis an artificial cornea, keratoprosthesis (KPro), which provides along-lasting medical solution for corneal blindness, pathology and injury.The CorNeat KPro implant is a patented synthetic cornea utilizing advanced cell technology to integrate artificial optics within resident ocular tissue.

Axcelis Announces Participation In Stifel 2020 Cross Sector Insight Conference

Retrieved on: 
Monday, June 1, 2020
Axcelis Technologies, Materials science, ACLS, Ion implantation, Implantation, Process, Semiconductor, Physical sciences, Chemistry, Natural sciences

BEVERLY, Mass., June 1, 2020 /PRNewswire/ --Axcelis Technologies, Inc. (NASDAQ: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate in the virtual Stifel 2020Cross Sector Insight ConferenceonJune 9th.

Key Points: 
  • BEVERLY, Mass., June 1, 2020 /PRNewswire/ --Axcelis Technologies, Inc. (NASDAQ: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate in the virtual Stifel 2020Cross Sector Insight ConferenceonJune 9th.
  • Management will host a fireside chat at8:00 a.m. Eastern Time.
  • Management will also be available for one on one meetings.
  • Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation systems, one of the most critical and enabling steps in the IC manufacturing process.

Axcelis Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 19, 2020
Axcelis Technologies, ACLS, Implantation

BEVERLY, Mass., May 19, 2020 /PRNewswire/ --Axcelis Technologies, Inc. (NASDAQ: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate in the following upcoming virtual investor conferences:

Key Points: 
  • BEVERLY, Mass., May 19, 2020 /PRNewswire/ --Axcelis Technologies, Inc. (NASDAQ: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate in the following upcoming virtual investor conferences:
    The 17th Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 27th.
  • Management will be available for virtual one on ones and small group meetings during the event.
  • The 48th Annual Cowen 2020 Technology, Media & Telecom Conference on Friday, May 29th at 12:30 pm ET.
  • Management will participate in a virtual video fireside chat and will also be available for one on one meetings.